I
Issa F. Khouri
Researcher at University of Texas MD Anderson Cancer Center
Publications - 420
Citations - 18794
Issa F. Khouri is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 71, co-authored 399 publications receiving 17746 citations. Previous affiliations of Issa F. Khouri include University of Texas Health Science Center at Houston & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.
Journal ArticleDOI
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt,Peter F. Thall,Issa F. Khouri,Xuemei Wang,Ira Braunschweig,Cindy Ippolitti,David F. Claxton,Michele L. Donato,J. Bruton,A. Cohen,Marilyn S. Davis,Borje S. Andersson,Paolo Anderlini,James Gajewski,Steven M. Kornblau,Michael Andreeff,Donna Przepiorka,Naoto T. Ueno,Jeffrey J. Molldrem,Richard E. Champlin +19 more
TL;DR: Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis.
Journal ArticleDOI
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Issa F. Khouri,Rima M. Saliba,Sergio Giralt,Ming Sheng Lee,Grace Julia Okoroji,Fredrick B. Hagemeister,Martin Korbling,Anas Younes,Cindy Ippoliti,James Gajewski,Peter McLaughlin,Paolo Anderlini,Michele L. Donato,Fernando Cabanillas,Richard E. Champlin +14 more
TL;DR: Nonablative chemotherapy with fludarabine/cyclophosphamide followed by allogeneic stem cell transplantation is a promising therapy for indolent lymphoma with minimal toxicity and myelosuppression.
Journal ArticleDOI
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Issa F. Khouri,J. Romaguera,Hagop M. Kantarjian,J L Palmer,William C. Pugh,M. Korbling,Fredrick B. Hagemeister,B. Samuels,Alma Rodriguez,Sergio Giralt,Anas Younes,Donna Przepiorka,David F. Claxton,Fernando Cabanillas,Richard E. Champlin +14 more
TL;DR: The Hyper-CVAD/MTX-Ara-C program followed by stem-cell transplantation is a promising new therapy for previously untreated patients with MCL.